A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease (NCT07499232)
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Who can join: Review the eligibility criteria below.
Location: Digestive Health Specialists of the Southeast — Dothan, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (160 Sites)
Showing the first 25 of 160 sites.
- Digestive Health Specialists of the Southeast — Dothan, Alabama
- East View Medical Research — Mobile, Alabama
- Clinnova Research — Anaheim, California
- Gastro Care Institute — Lancaster, California
- United Gastroenterologists — Los Alamitos, California
- TLC Clinical Research Inc — Los Angeles, California
- GastroIntestinal Bioscience — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
- Medical Associates Research Group, Inc. — San Diego, California
- Peak Gastroenterology Associates — Colorado Springs, Colorado
- Medical Research Center of Connecticut — Hamden, Connecticut
- Green Leaf Clinical Trials — Jacksonville, Florida
- Sanchez Clinical Research, Inc — Miami, Florida
- Biodax Medical Research Trials — Miami, Florida
- GI Pros Research — Naples, Florida
- GCP Clinical Research — Tampa, Florida
- Morehouse School of Medicine — Atlanta, Georgia
- Atlanta Gastroenterology Associates — Atlanta, Georgia
- Gastroenterology Associates of Central GA — Macon, Georgia
- Comprehensive Gastrointestinal Health Libertyville — Northbrook, Illinois
- Cotton-O'Neil Clinical Research Center — Topeka, Kansas
- Gastroenterology Clinic of Acadiana — Lafayette, Louisiana
- Woodholme Gastroenterology Associates — Glen Burnie, Maryland
- Lucida Clinical Trials — New Bedford, Massachusetts
- Michigan Center of Medical Research — Farmington Hills, Michigan
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn Disease
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease — Lutherville, Maryland
- Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial — New Haven, Connecticut
- A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease — Portland, Oregon
- Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) — Ottawa, Ontario
- A Long-term Extension Study of Ustekinumab in Pediatric Participants — Atlanta, Georgia
- Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease — Atlanta, Georgia
Explore by condition: All Crohn Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.